^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD20 positive

    i
    Other names: CD20, MS4A1, Membrane Spanning 4-Domains A1, Membrane-Spanning 4-Domains, Subfamily A, Member 1, Leukocyte Surface Antigen Leu-16, B-Lymphocyte Antigen CD20, CD20 Antigen, Membrane-Spanning 4-Domains Subfamily A Member 1, B-Lymphocyte Cell-Surface Antigen B1, B-Lymphocyte Surface Antigen B1, CD20 Receptor, LEU-16, CVID5, MS4A2
    Entrez ID:
    494216
    Related biomarkers:
    Expression
    Others
    1d
    Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation (clinicaltrials.gov)
    P2, N=35, Recruiting, The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    cyclophosphamide • Inokai (orelabrutinib) • Polivy (polatuzumab vedotin-piiq)
    4d
    Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • celecoxib oral
    5d
    Successful Treatment of Tumor-Induced Lactic Acidosis With Tris-Hydroxymethyl Aminomethane (THAM). (PubMed, Kidney Med)
    The therapeutic use of isotonic bicarbonate solution is limited owing to paradoxical intracellular acidosis. Tris-hydroxymethyl aminomethane rapidly corrects intracellular acidosis, restoring hepatic lactate clearance through the Cori cycle.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    6d
    Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL (clinicaltrials.gov)
    P2, N=50, Recruiting, Ou Bai, MD/PHD
    New P2 trial
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Epidaza (chidamide)
    7d
    Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP (clinicaltrials.gov)
    P3, N=200, Recruiting, Ou Bai, MD/PHD
    New P3 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • Epidaza (chidamide)
    7d
    Blastoid Mantle Cell Lymphoma in the Leukemic Phase: Resolving a Morphological Dilemma Through Flow Cytometry. (PubMed, Cureus)
    Flow cytometric immunophenotyping demonstrated bright CD45 expression with low side scatter and positivity for CD19, CD20, CD38, CD5, CD79b, and FMC7 with negativity for CD34, CD23, CD200, and CD10, suggesting blastoid transformation of MCL rather than de novo ALL. This case highlights the critical role of flow cytometry in distinguishing blastoid MCL from acute leukemia, thereby preventing misdiagnosis and ensuring appropriate therapeutic decision-making.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • CD38 (CD38 Molecule) • CDK4 (Cyclin-dependent kinase 4) • CD79B (CD79b Molecule) • CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD5 (CD5 Molecule) • CD200 (CD200 Molecule) • MME (Membrane Metalloendopeptidase) • CDKN2C (Cyclin Dependent Kinase Inhibitor 2C) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    TP53 mutation • CD20 positive • CDKN2A deletion • RB1 deletion • PTPRC expression
    7d
    MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL (clinicaltrials.gov)
    P2, N=145, Recruiting, Ruijin Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    lenalidomide • Gazyva (obinutuzumab) • Inokai (orelabrutinib)
    14d
    Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZL (clinicaltrials.gov)
    P2, N=65, Active, not recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    cyclophosphamide • vincristine • Inokai (orelabrutinib) • Anruixi (zuberitamab)
    14d
    SKYGLO: An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma (clinicaltrials.gov)
    P3, N=1130, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Dec 2027 --> Oct 2027
    Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    16d
    SWOG S0016: S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P3, N=571, Completed, SWOG Cancer Research Network | Active, not recruiting --> Completed
    Trial completion
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Bexxar (iodine I 131 tositumomab)
    16d
    Diffuse large B-cell lymphoma as a rare cause of small bowel obstruction: case report and literature review. (PubMed, Int J Surg Case Rep)
    The postoperative course was uneventful and the patient remained disease-free at 8-month follow-up after completing R-CHOP chemotherapy...Although rare, DLBCL should be considered as a differential diagnosis in unexplained SBO. Early recognition and a multidisciplinary management strategy improve prognosis.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6) • MME (Membrane Metalloendopeptidase)
    |
    CD20 positive
    |
    Rituxan (rituximab)
    18d
    Epcoritamab in Previously Treated WM (clinicaltrials.gov)
    P2, N=20, Recruiting, Gottfried von Keudell, MD PhD | Trial primary completion date: Oct 2025 --> Apr 2027
    Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    CD20 positive
    |
    Epkinly (epcoritamab-bysp)